UNC-Chapel Hill spinout Falcon Therapeutics has raised a seed round from unnamed backers.
Falcon Therapeutics, a US-based brain cancer-focused biotech spinout from University of North Carolina (UNC) at Chapel Hill, today obtained $700,000 of seed money from undisclosed investors today, according to a regulatory filing.
Founded in 2015 by Shawn Hingtgen, an assistant professor in the Division of Molecular Pharmaceutics at UNC’s Eshelman School of Pharmacy, the spinout is working on a brain cancer treatment that uses neural stem cells collected through a biopsy the patient’s own skin.
The spinout, headed by chief…